A new treatment using gut microbiome to help patients with severe lung injury from viruses
A Novel Synthetic Biology-Derived Microbiome Therapeutic to Treat Viral-Induced Acute Respiratory Distress Syndrome (ARDS)
['FUNDING_SBIR_2'] · RISE THERAPEUTICS, LLC · NIH-10764911
This study is exploring a new way to help people with acute respiratory distress syndrome (ARDS) from viral infections by looking at how certain immune cells and gut bacteria can work together to reduce inflammation and improve recovery.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | RISE THERAPEUTICS, LLC (nih funded) |
| Locations | 1 site (Rockville, UNITED STATES) |
| Trial ID | NIH-10764911 on ClinicalTrials.gov |
What this research studies
This research investigates a novel therapeutic approach for treating acute respiratory distress syndrome (ARDS) caused by viral infections. It focuses on the role of neutrophils, a type of immune cell, in the inflammatory response associated with ARDS. By leveraging the gut microbiome, the study aims to modulate immune responses and reduce inflammation, potentially improving patient outcomes. The approach is designed to be rapid and broadly applicable, addressing the urgent need for effective treatments in the context of viral pandemics.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals experiencing severe lung injury or ARDS as a result of viral infections.
Not a fit: Patients with ARDS caused by non-viral factors or those who do not have significant neutrophil activation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients suffering from ARDS due to viral infections.
How similar studies have performed: While the specific approach of using gut microbiome modulation for ARDS is novel, similar strategies targeting immune responses have shown promise in other contexts.
Where this research is happening
Rockville, UNITED STATES
- RISE THERAPEUTICS, LLC — Rockville, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: FURLAN FREGUIA, CHRISTIAN — RISE THERAPEUTICS, LLC
- Study coordinator: FURLAN FREGUIA, CHRISTIAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acute Pulmonary Injury, Acute Lung Injury, pulmonary injury, pulmonary tissue injury, lung injury